对紫杉醇和多西他赛过敏后使用纳米白蛋白结合型紫杉醇成功治疗。
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
作者信息
de Leon Maria C B, Bolla Sridhar, Greene Barbra, Hutchinson Lauren, Del Priore Giuseppe
机构信息
Indiana University, Gynecologic Oncology Division, 535 Barnhill Drive, Rm 435, Indianapolis, IN 46202, USA.
American Health Network Hematology Oncology, 1111 Ronald Reagan Pkwy #B1500, Avon, IN 46123, USA.
出版信息
Gynecol Oncol Case Rep. 2013 May 14;5:70-1. doi: 10.1016/j.gynor.2013.05.003. eCollection 2013.
Abstract
•First case report of successfully treating severe paclitaxel and docetaxel hypersensitivity reaction with nab-paclitaxel•We demonstrated that nab-paclitaxel is a safe taxane chemotherapy treatment option for patients who could not tolerate paclitaxel or docetaxel.
摘要
•首例用纳米白蛋白结合型紫杉醇成功治疗严重紫杉醇和多西他赛过敏反应的病例报告•我们证明，对于无法耐受紫杉醇或多西他赛的患者，纳米白蛋白结合型紫杉醇是一种安全的紫杉烷类化疗选择。
相似文献
1
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.对紫杉醇和多西他赛过敏后使用纳米白蛋白结合型紫杉醇成功治疗。
Gynecol Oncol Case Rep. 2013 May 14;5:70-1. doi: 10.1016/j.gynor.2013.05.003. eCollection 2013.
2
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.多西他赛过敏反应后使用白蛋白结合型紫杉醇：病例报告及文献综述
Acta Biomed. 2017 Oct 23;88(3):329-333. doi: 10.23750/abm.v88i3.6138.
3
4
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.纳米白蛋白结合型（nab）紫杉醇与聚山梨酯基多西他赛相比，在多种异种移植模型中的疗效改善与HER2和SPARC状态的关系。
Anticancer Drugs. 2008 Oct;19(9):899-909. doi: 10.1097/CAD.0b013e32830f9046.
5
Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses.纳米白蛋白结合型紫杉醇相关的光敏反应：一名非小细胞肺癌女性患者的病例报告及紫杉烷类相关光皮肤病的综述
Dermatol Pract Concept. 2015 Apr 30;5(2):121-4. doi: 10.5826/dpc.0502a24. eCollection 2015 Apr.
6
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.白蛋白结合型紫杉醇对比多西他赛用于既往治疗的晚期 NSCLC 的 3 期临床试验
J Thorac Oncol. 2021 Sep;16(9):1523-1532. doi: 10.1016/j.jtho.2021.03.027. Epub 2021 Apr 27.
7
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.白蛋白紫杉醇对比多西他赛作为转移性乳腺癌一线化疗的 II 期临床试验：总生存的最终分析。
Clin Breast Cancer. 2012 Oct;12(5):313-21. doi: 10.1016/j.clbc.2012.05.001. Epub 2012 Jun 23.
8
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2 Early-stage Breast Cancer.随机多中心 II 期试验：比较新辅助治疗在 HER2 早期乳腺癌中使用nab-紫杉醇联合 FEC 与多西紫杉醇联合 FEC 的疗效。
Clin Breast Cancer. 2018 Dec;18(6):474-480. doi: 10.1016/j.clbc.2018.06.012. Epub 2018 Jun 27.
9
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.与多西他赛相比，纳布紫杉醇作为转移性乳腺癌一线治疗方案时，无进展生存期显著更长。
J Clin Oncol. 2009 Aug 1;27(22):3611-9. doi: 10.1200/JCO.2008.18.5397. Epub 2009 May 26.
10
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.纳武利尤单抗联合紫杉醇一线治疗伴有不良预后因素的转移性乳腺癌的回顾性分析。
Breast Cancer Res Treat. 2013 Apr;138(3):829-37. doi: 10.1007/s10549-013-2447-8. Epub 2013 Apr 6.
引用本文的文献
1
Successful desensitization in paclitaxel-induced anaphylaxis: The role of skin testing and environmental sensitization.紫杉醇诱导的过敏反应中成功脱敏：皮肤试验和环境致敏的作用。
Asia Pac Allergy. 2025 Sep;15(3):225-227. doi: 10.5415/apallergy.0000000000000198. Epub 2025 Mar 17.
2
Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study.对紫杉醇发生过敏反应后使用纳米白蛋白结合型紫杉醇的安全性：一项单机构回顾性研究。
Gynecol Oncol Rep. 2024 Aug 3;55:101475. doi: 10.1016/j.gore.2024.101475. eCollection 2024 Oct.
3
Interdisciplinary Healthcare Team Experience of Carboplatin and Oxaliplatin Desensitizations in a Tertiary Referral University Hospital.三级转诊大学医院中卡铂和奥沙利铂脱敏治疗的跨学科医疗团队经验
J Asthma Allergy. 2023 Jul 21;16:743-753. doi: 10.2147/JAA.S419722. eCollection 2023.
4
Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).组胺 2 拮抗剂短缺对紫杉醇过敏反应发生率的影响：对法国（PACLIREACT 研究）预用药方案的重新考虑。
Eur J Clin Pharmacol. 2023 Sep;79(9):1229-1238. doi: 10.1007/s00228-023-03536-x. Epub 2023 Jul 13.
5
A meta-analysis of the incidence and risk of skin toxicity with nab-paclitaxel and paclitaxel in cancer treatment.纳米白蛋白结合型紫杉醇与紫杉醇在癌症治疗中皮肤毒性发生率及风险的荟萃分析。
Am J Transl Res. 2023 Jun 15;15(6):4279-4290. eCollection 2023.
6
Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.癌症治疗中的过敏反应：抗肿瘤治疗诱导的超敏反应。
Int J Mol Sci. 2023 Feb 15;24(4):3886. doi: 10.3390/ijms24043886.
7
Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.从纳米技术表征实验室对纳米材料的免疫学特性研究中吸取的经验教训。
Front Immunol. 2022 Oct 10;13:984252. doi: 10.3389/fimmu.2022.984252. eCollection 2022.
8
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider.癌症治疗的预处理：血液学/肿瘤学医疗服务提供者入门指南。
J Adv Pract Oncol. 2021 Nov;12(8):810-832. doi: 10.6004/jadpro.2021.12.8.4. Epub 2021 Nov 1.
9
Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.预处理方案预防化疗药物过敏反应的文献综述。
Clin Rev Allergy Immunol. 2022 Jun;62(3):534-547. doi: 10.1007/s12016-022-08932-2. Epub 2022 Mar 8.
10
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.多西他赛过敏反应后使用白蛋白结合型紫杉醇：病例报告及文献综述
Acta Biomed. 2017 Oct 23;88(3):329-333. doi: 10.23750/abm.v88i3.6138.
本文引用的文献
1
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.白蛋白结合型紫杉醇纳米粒治疗铂类耐药复发性或持续性卵巢癌、输卵管癌或原发性腹膜癌的 II 期评估：一项妇科肿瘤学组研究。
Gynecol Oncol. 2011 Jul;122(1):111-5. doi: 10.1016/j.ygyno.2011.03.036. Epub 2011 Apr 15.
2
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.艾日布林用于治疗对紫杉醇严重过敏反应的妇科癌症患者。
需注意，你提供的原文中药物名称有误，正确的应该是“Abraxane”对应“艾日布林” ，“paclitaxel”对应“紫杉醇” ，这里按照正确内容翻译了。如果按照你原文的错误药物名翻译，译文为：纳米白蛋白结合型紫杉醇用于治疗对紫杉醇严重过敏反应的妇科癌症患者。
Int J Gynecol Cancer. 2009 Oct;19(7):1281-3. doi: 10.1111/IGC.0b013e3181a38e2f.
3
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.在一项女性癌症项目中紫杉醇与多西他赛之间的交叉敏感性。
Gynecol Oncol. 2006 Jan;100(1):149-51. doi: 10.1016/j.ygyno.2005.08.004. Epub 2005 Sep 28.
4
Successful parenteral desensitization to paclitaxel.成功的紫杉醇胃肠外脱敏治疗。
J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):42-6. doi: 10.1016/s0091-6749(96)70281-6.
5
Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions.尽管使用了大剂量类固醇并延长输注时间，但仍出现紫杉醇相关的超敏反应。
Gynecol Oncol. 1995 Feb;56(2):316-8. doi: 10.1006/gyno.1995.1054.
Zotero 插件